Loader

Pathways

PathWhiz ID Pathway Meta Data

PW127488

Pw127488 View Pathway
drug action

Piperacillin Action Pathway

Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
Piperacillin is a penicillin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. It is combined with tazobactam to treat piperacillin-resistant, piperacillin/tazobactam­ susceptible, β-lactamase generating strains of several bacteria. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, Piperacillin inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that Piperacillin interferes with an autolysin inhibitor.

PW144446

Pw144446 View Pathway
drug action

Piperacillin Drug Metabolism Action Pathway

Homo sapiens

PW127441

Pw127441 View Pathway
drug action

Piperaquine Action Pathway

Plasmodium falciparum
Piperaquine is an antimalarial agent first synthesized in the 1960's and used throughout China. Its use declined in the 1980's as piperaquine resistant strains of Plasmodium falciparum appeared and artemisinin derivatives became available. It has come back into use in combination with the artemisinin derivative Artenimol as part of the combination product Eurartesim. The mechanism of piperaquine inhibition of the haem detoxification pathway is unknown but is expected to be similar to that of Chloroquine.

PW146703

Pw146703 View Pathway
drug action

Piperaquine Drug Metabolism Action Pathway

Homo sapiens

PW144708

Pw144708 View Pathway
drug action

Piperazine Drug Metabolism Action Pathway

Homo sapiens

PW146107

Pw146107 View Pathway
drug action

Piperonyl butoxide Drug Metabolism Action Pathway

Homo sapiens

PW144365

Pw144365 View Pathway
drug action

Pipobroman Drug Metabolism Action Pathway

Homo sapiens

PW128414

Pw128414 View Pathway
drug action

Pipotiazine Dopamine Antagonist Action Pathway

Homo sapiens
Pipotiazine acts as an antagonist (blocking agent) on different postsysnaptic receptors -on dopaminergic-receptors (subtypes D1, D2, D3 and D4 - different antipsychotic properties on productive and unproductive symptoms), on serotonergic-receptors (5-HT1 and 5-HT2, with anxiolytic, antidepressive and antiaggressive properties as well as an attenuation of extrapypramidal side-effects, but also leading to weight gain, fall in blood pressure, sedation and ejaculation difficulties), on histaminergic-receptors (H1-receptors, sedation, antiemesis, vertigo, fall in blood pressure and weight gain), alpha1/alpha2-receptors (antisympathomimetic properties, lowering of blood pressure, reflex tachycardia, vertigo, sedation, hypersalivation and incontinence as well as sexual dysfunction, but may also attenuate pseudoparkinsonism - controversial) and finally on muscarinic (cholinergic) M1/M2-receptors (causing anticholinergic symptoms like dry mouth, blurred vision, obstipation, difficulty/inability to urinate, sinus tachycardia, ECG-changes and loss of memory, but the anticholinergic action may attenuate extrapyramidal side-effects).

PW145485

Pw145485 View Pathway
drug action

Pipotiazine Drug Metabolism Action Pathway

Homo sapiens

PW176351

Pw176351 View Pathway
metabolic

Pipotiazine Predicted Metabolism Pathway

Homo sapiens
Metabolites of sildenafil are predicted with biotransformer.